Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print International panel updates treatment guidelines for HIV infection

International panel updates treatment guidelines for HIV infection

August 04, 2008

An evaluation of recent data has led to an update in the guidelines and recommendations for antiretroviral treatment of adult human immunodeficiency virus (HIV) infection, according to an article in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

Scott M. Hammer, M.D., of Columbia University College of Physicians and Surgeons, New York, and the International AIDS Society-USA Panel, presented the recommendations of the panel at a JAMA media briefing on HIV/AIDS.




The field of antiretroviral therapy continues to evolve rapidly, and, to maintain the highest possible standard of care, treatment guidelines must continually be refined to assist the complex decision-making process, according to the authors. "For a disease that has been transformed from almost uniformly fatal to manageable over decades, the impact of treatment decisions is substantial." They add that the availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral patients warrants an update of the International AIDS Society-USA guidelines.

Dr. Hammer and members of the panel analyzed new data in the field from the last two years to provide guidelines in key areas of antiretroviral management, including when to start therapy, choice of initial regimens, patient monitoring, and the approach to treatment failure. The latter emphasizes the role of recently approved drugs in assisting clinicians with constructing regimens that will keep HIV suppressed even in the face of multidrug resistant virus.

When to Start Antiretroviral Therapy

New data and considerations support initiating therapy before CD4 cell count declines to less than 350/μL. In patients with 350 CD4 cells/µL or more, patient readiness, drug interactions, adherence challenges, toxicities and cost should be considered when determining whether to initiate therapy.

Rapid decline in CD4 cell count (i.e., more than 100/μL per year), a plasma HIV-1 RNA level more than 100,000 copies/mL, risk factors for cardiovascular disease, and the presence of certain other diseases (e.g., active hepatitis B or C virus co-infection and HIV-associated nephropathy [a disease affecting the kidneys]) should be considered in deciding whether to initiate therapy in patients with CD4 cell counts more than 350/μl.

What Antiretroviral Regimen to Start

The authors write that the initial regimen must be individualized, particularly in the presence of other existing illnesses, but usually will include efavirenz or a ritonavir-boosted protease inhibitor plus two nucleoside (or nucleoside plus nucleotide) reverse transcriptase inhibitors (nRTIs). Recommended nRTIs in the initial regimen are the fixed-dose combinations tenofovir/emtricitabine or abacavir/lamivudine. Simplicity of therapy, pill number, tolerability, desire for pregnancy, drug interactions and primary drug resistance are likely to influence the choice between these recommended options.

Patient Monitoring

The goal of antiretroviral therapy is to reduce and maintain a plasma HIV-1 RNA level of less than 50 copies/mL. Plasma HIV-1 RNA levels should be monitored frequently when treatment is started or changed for virologic failure (e.g., at 2, 4, 8, and every 4 weeks thereafter) until it reaches levels below the assay detection limits, and regularly thereafter (e.g., 3-4 times per year). Genotypic testing for drug resistance should be performed for certain patients. Appropriate assessment of other conditions and monitoring for toxicity should be performed before initiating treatment and during follow-up.

Changing Therapies

Virologic failure on an initial nonnucleoside reverse transcriptase inhibitor (NNRTI)- or ritonavir-boosted protease inhibitor-based regimen should be treated early with, ideally, three fully active drugs. For multi-drug resistance, three active drugs, including new classes of agents whenever possible, should be used.

The appropriate use of new agents, such as raltegravir (an integrase strand transfer inhibitor), maraviroc (a CCR5 antagonist), and etravirine (a "second generation" NNRTI), in combination with older agents can help achieve the goal of maintaining a plasma HIV-1 RNA level below 50 copies/ml even in patients with high degrees of treatment experience and multidrug resistant virus.

The authors write that despite advances in the treatment of HIV infection, "disease management remains challenged by toxicities, maintenance of adherence, clinical manifestations related to both the drugs and the HIV infection itself, and the threat of drug resistance. Sustainability and expansion of the progress achieved will depend on maintaining a robust drug development pipeline and the ability to deliver effective therapy and monitoring tools to the world's affected populations."

"With creativity and political will, the progress and individualized approach to antiretroviral therapy evident in the developed world can be adapted to the public health approach in the developing world, where 90 percent of the world's HIV-infected population lives."

JAMA and Archives Journals



Related Antiretroviral Current Events and Antiretroviral News Articles Antiretroviral Current Events and Antiretroviral News RSS Antiretroviral Current Events and Antiretroviral News RSS
Many pregnant women avoid HIV screening in Africa
'Prevention is the best cure' is a common expression, but what happens if preventative measures are not used? A large proportion of pregnant Ugandan women are going out of their way not to be HIV tested, increasing the risk of mother-to-child transmission.

Taking medicine for HIV proves hard to swallow for many people
Highly active antiretroviral therapy has increased the longevity and quality of life for people living with human immunodeficiency virus. But it requires strict adherence in taking the medicine, something that is extremely difficult for many individuals to do.

Feelings of stigmatization may discourage HIV patients from proper care
The feeling of stigmatization that people living with HIV often experience doesn't only exact a psychological toll -new UCLA research suggests it can also lead to quantifiably negative health outcomes.

Maternal HIV-1 treatment protects against transmission to newborns
Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding.

Research shows treating HIV-AIDS with interleukin-2 is ineffective
An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

Nurses safely and effectively prescribe antiretroviral drugs in pilot program
Given sufficient training and support, nurses can safely and effectively prescribe antiretroviral therapy (ART) to patients with HIV, according to a Rwandan study published in this week's PLoS Medicine.

Study highlights HIV/AIDS challenge in American prison system
HIV/Aids is up to five times more prevalent in American prisons than in the general population. Adherence to treatment programs can be strictly monitored in prison.

Study finds nontuberculous mycobacteria lung disease on the rise in the United States
Nontuberculous mycobacteria (NTM) are environmental organisms found in both water and soil that can cause severe pulmonary (lung) disease in humans. Pulmonary NTM is on the rise in the United States, according to a large study of people hospitalized with the condition.

HIV vaccine regimen demonstrates modest preventive effect in Thailand clinical study
In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand.

Updated Guidelines Highlight Primary Care Needs of Those Living With HIV
With HIV patients living longer thanks to advances in treatment, the primary care needs of those living with HIV have never been more important.
More Antiretroviral Current Events and Antiretroviral News Articles
Mortal Combat: AIDS Denialism and the Struggle for Antiretrovirals in South Africa

Mortal Combat: AIDS Denialism and the Struggle for Antiretrovirals in South Africa
by Nicoli Nattrass (Author)

The AIDS pandemic and "denialism" is an international issue and South Africa is a flash point case study. "Mortal Combat" is a history of AIDS policy in South Africa. It exposes the strategy and tactics of AIDS denialists and focuses on the struggle for antiretrovirals to prevent mother-to-child transmission of HIV and to extend the lives of people living with AIDS.

Thing With No Name

Thing With No Name
Starring: Danisile; Ntombeleni
Directed By: Sarah Friedland
Also With: Sarah Friedland (Producer), Sarah Friedland (Writer)



AIDS in Africa

AIDS in Africa
Also With: MacNeil / Lehrer Productions (Producer)

The AIDS crisis in Africa is the subject of this 2001 NewsHour series. Correspondents report on the situation in three countries: Malawi, Botswana and Senegal. Also included is a discussion about the international community's role in combating the epidemic. A warning: segments in the series contain strong images and frank conversations about sexual habits.

Science Sold Out: Does HIV Really Cause AIDS?

Science Sold Out: Does HIV Really Cause AIDS?
by Rebecca Culshaw (Author), Harvey Bialy (Foreword)

There are many well-established scientific reasons that the HIV/AIDS hypothesis is highly doubtful. In Science Sold Out, Rebecca Culshaw describes her slow uncovering of these reasons over her years researching HIV for her work constructing mathematical models of its interaction with the immune system. It is rare that a researcher who has received funding to study HIV ever expresses any doubt in the paradigm, and an even rarer event still when she abandons the field altogether. This book focuses on the changing definition of AIDS and the flaws in all HIV testing. In a much broader sense, it explains how the current, government-based structure of scientific research has corrupted science as the search for truth. It offers not only scientific reasons for HIV/AIDS being untenable, but also...

From access to adherence: The challenges of antiretroviral treatment

From access to adherence: The challenges of antiretroviral treatment
by A., et al., Davey, S., Gerrits, T., Hodgkin, C. Hardon (Author)

As access to ARVs becomes assured, the world needs to place equal effort in ensuring that every ART patient receives adequate adherence support. The authors of this book report on the experiences from successful treatment programmes in three countries in sub-Saharan Africa at the forefront of the roll-out of ARVs. The voices of the patients, their families, community members and the health workers who care for them have been reported faithfully. They speak of the impact of ART on their daily lives and of the key challenges involved in sustaining the necessary high level of adherence to treatment. Their real life experience is valid and needs to be considered by health programme managers who are planning the expansion of ARV treatment programmes.

  Access to Treatment in the Private-Sector Workplace: The Provision of Antiretroviral Therapy by Three Companies in South Africa (A UNAIDS Publication)
by UNAIDS (Author)

Companies cannot ignore HIV; it is a business issue demanding a response now and influencing longer term strategic planning. HIV infection among employees poses a significant threat to operational stability and future profitability. This study outlines how three major companies operating in South Africa have recognized both the challenges HIV poses and their moral duty of care, and have implemented programs to treat and care for employees and their families.

  Gale Encyclopedia of Medicine: Antiretroviral drugs
by Samuel D. Uretsky PharmD (Author)

The article is excerpted from Gale Encyclopedia of Medicine.

Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major topics. Disease/disorder articles typically cover definition; description; causes and symptoms; diagnosis; treatments; prevention; and more. Test/treatment articles typically cover definition; purposes; precautions; preparation; risks; normal and abnormal results; and much more. This second edition includes more than 200 new entries, 300 updated entries, approximately 650 color...

  Start Time for Antiretrovirals Not Gender Specific.(Brief Article)(Statistical Data Included): An article from: Family Practice News
by Barbara Baker (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on March 15, 2000. The length of the article is 2876 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Start Time for Antiretrovirals Not Gender Specific.(Brief Article)(Statistical Data Included)
Author: Barbara Baker
Publication: Family Practice News (Magazine/Journal)
Date: March 15, 2000
Publisher: International Medical News Group
Volume: 30 Issue: 6 Page: 19

Article Type: Brief Article, Statistical Data Included

Distributed by Thomson...

  Antiretrovirals Quell Kaposi's in Most HIV-Infected Patients.: An article from: Family Practice News
by Sherry Boschert (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 1999. The length of the article is 550 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Antiretrovirals Quell Kaposi's in Most HIV-Infected Patients.
Author: Sherry Boschert
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 1999
Publisher: International Medical News Group
Volume: 29 Issue: 17 Page: 22

Distributed by Thomson...

  The imperative to treat: the South African State's Constitutional obligations to provide antiretroviral medicines.: An article from: Health Law Review
by Lisa Forman (Author)

This digital document is an article from Health Law Review, published by Health Law Institute on December 22, 2003. The length of the article is 5066 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: The imperative to treat: the South African State's Constitutional obligations to provide antiretroviral medicines.
Author: Lisa Forman
Publication: Health Law Review (Magazine/Journal)
Date: December 22, 2003
Publisher: Health Law Institute
Volume: 12 Issue: 1 Page: 9(7)

Distributed by Thomson...

© 2009 BrightSurf.com